Chinese pharma company Sinovac’s Covid-19 vaccine CoronaVac has demonstrated 67% efficacy against symptomatic Covid-19 infections in a large real-world study in Chile. The vaccine showed effectiveness against admission to ICU, hospitalisation and death, with respective efficacy rates of 89%, 85% and 80%, according to a Chilean government report.
A US Centers for Disease Prevention (CDC) advisory panel is scheduled to meet on Friday 23 April to decide whether to continue the pause of J&J’s Covid-19 vaccine rollout. The panel will examine additional cases that have come up and assess risks arising from its administration. The use of the J&J vaccine was suspended following six cases of unusual brain blood clots reported in women out of approximately seven million people who received the one-shot vaccine in the US.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Eli Lilly has requested that the US Food and Drug Administration (FDA) revoke the emergency use authorisation (EUA) for bamlanivimab (LY-CoV555) 700mg as a Covid-19 monotherapy. The request comes as Lilly transitions to only supplying bamlanivimab and etesevimab in combination to treat Covid-19 in the country. Lilly’s request was in view of the surge in Covid-19 variants across the US and not related to any safety concerns.
